You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

~ Buy the RAPIVAB (peramivir) Drug Profile, 2024 PDF Report in the Report Store ~

RAPIVAB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are two patents protecting this drug.

This drug has forty-two patent family members in fourteen countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

DrugPatentWatch® Generic Entry Outlook for Rapivab

Rapivab was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RAPIVAB?
  • What are the global sales for RAPIVAB?
  • What is Average Wholesale Price for RAPIVAB?
Summary for RAPIVAB
International Patents:42
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 142
Clinical Trials: 3
Patent Applications: 1,074
Drug Prices: Drug price information for RAPIVAB
What excipients (inactive ingredients) are in RAPIVAB?RAPIVAB excipients list
DailyMed Link:RAPIVAB at DailyMed
Drug patent expirations by year for RAPIVAB
Drug Prices for RAPIVAB

See drug prices for RAPIVAB

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RAPIVAB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OxfordPhase 2
BioCryst PharmaceuticalsPhase 3
Johns Hopkins UniversityPhase 4

See all RAPIVAB clinical trials

US Patents and Regulatory Information for RAPIVAB

RAPIVAB is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAPIVAB is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting RAPIVAB

Antiviral treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Antiviral treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

Antiviral treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RAPIVAB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocryst Alpivab peramivir EMEA/H/C/004299
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Withdrawn no no no 2018-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for RAPIVAB

When does loss-of-exclusivity occur for RAPIVAB?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06341592
Patent: Intramuscular antiviral treatments
Estimated Expiration: ⤷  Sign Up

Patent: 07215156
Patent: Intravenous antiviral treatments
Estimated Expiration: ⤷  Sign Up

Patent: 13216632
Patent: INTRAVENOUS ANTIVIRAL TREATMENTS
Estimated Expiration: ⤷  Sign Up

Patent: 16262644
Patent: INTRAVENOUS ANTIVIRAL TREATMENTS
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0621552
Patent: tratamentos antivirais intramusculares
Estimated Expiration: ⤷  Sign Up

Patent: 0707769
Patent: tratamentos antivirais intravenosos
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 42260
Patent: TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 49090
Patent: TRAITEMENTS ANTIVIRAUX INTRAMUSCULAIRES (INTRAMUSCULAR ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

China

Patent: 1420948
Patent: Intramuscular antiviral treatments
Estimated Expiration: ⤷  Sign Up

Patent: 4784166
Patent: Antiviral compound, dosage form including same, and uses thereof
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 5483
Patent: ВНУТРИВЕННЫЙ СПОСОБ ЛЕЧЕНИЯ СЕЗОННОГО ГРИППА (INTRAVENOUS METHOD FOR TREATING A SEASONAL INFLUENZA)
Estimated Expiration: ⤷  Sign Up

Patent: 0870263
Patent: ВНУТРИВЕННЫЙ СПОСОБ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
Estimated Expiration: ⤷  Sign Up

Patent: 0870430
Patent: ВНУТРИМЫШЕЧНЫЕ АНТИВИРУСНЫЕ СПОСОБЫ ЛЕЧЕНИЯ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 86626
Patent: TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 12250
Patent: 抗病毒化合物、包含該化合物的劑型及其用途 (ANTIVIRAL COMPOUNDS, UNIT DOSAGE FORM COMPRISING SAID COMPOUNDS AND USE THEREOF)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 73202
Estimated Expiration: ⤷  Sign Up

Patent: 09533428
Estimated Expiration: ⤷  Sign Up

Patent: 09538822
Estimated Expiration: ⤷  Sign Up

Patent: 13256527
Patent: INTRAVENOUS ANTIVIRAL TREATMENT
Estimated Expiration: ⤷  Sign Up

Patent: 15180695
Patent: 静脈におけるウイルスの治療 (INTRAVENOUS ANTIVIRAL TREATMENT)
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 6063
Patent: INTRAVENOUS ANTIVIRAL TREATMENTS
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 08010394
Patent: TRATAMIENTOS ANTIVIRALES INTRAVENOSOS. (INTRAVENOUS ANTIVIRAL TREATMENTS.)
Estimated Expiration: ⤷  Sign Up

Patent: 08013140
Patent: TRATAMIENTOS ANTIVIRALES INTRAMUSCULARES. (INTRAMUSCULAR ANTIVIRAL TREATMENTS.)
Estimated Expiration: ⤷  Sign Up

Patent: 20002008
Patent: TRATAMIENTOS ANTIVIRALES INTRAVENOSOS. (INTRAVENOUS ANTIVIRAL TREATMENTS.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 0538
Patent: Intravenous antiviral treatments
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 0809012
Patent: Intravenous antiviral treatments
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1992585
Estimated Expiration: ⤷  Sign Up

Patent: 2194015
Estimated Expiration: ⤷  Sign Up

Patent: 2267754
Estimated Expiration: ⤷  Sign Up

Patent: 2323339
Estimated Expiration: ⤷  Sign Up

Patent: 2475176
Estimated Expiration: ⤷  Sign Up

Patent: 080096829
Patent: INTRAVENOUS ANTIVIRAL TREATMENTS
Estimated Expiration: ⤷  Sign Up

Patent: 140132778
Patent: INTRAVENOUS ANTIVIRAL TREATMENTS
Estimated Expiration: ⤷  Sign Up

Patent: 160129105
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 180024027
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 190072681
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 200143519
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 210076189
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 210135632
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Patent: 230003248
Patent: 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RAPIVAB around the world.

Country Patent Number Title Estimated Expiration
Japan 2013256527 INTRAVENOUS ANTIVIRAL TREATMENT ⤷  Sign Up
European Patent Office 1040094 COMPOSES DES CYCLOPENTANE ET CYCLOPENTENE CONVENANT COMME INHIBITEURS DE NEURAMINIDASE (SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS) ⤷  Sign Up
Mexico 2020002008 TRATAMIENTOS ANTIVIRALES INTRAVENOSOS. (INTRAVENOUS ANTIVIRAL TREATMENTS.) ⤷  Sign Up
Australia 2200199 ⤷  Sign Up
Japan 5118502 ⤷  Sign Up
Austria 425955 ⤷  Sign Up
South Korea 20160129105 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.